Proactive Investors - Run By Investors For Investors

Genetic Technologies exceeds fiscal 2012 revenues for DNA technology

Genetic Technologies exceeds fiscal 2012 revenues for DNA technology

Genetic Technologies (ASX: GTG) has already surpassed gross revenues generated by its non-coding DNA technology licensing program in the 2012 financial year in just the first five months of the 2013 financial year.

Importantly, the non-dilutive funding has added substantially to the company’s cash reserves as at 30 November 2012, which exceeded $7.5 million.

The intellectual property out-licensing program provides a contracted annuity stream of $5.5 million through to 2015.

Over 65 licences have been awarded, generating around $70 million in revenue so far, with $13.5 million of that secured from nine contracts in 2011 alone – marking a record licensing year for Genetic.

The company has several patent families protecting the use of its non-coding DNA for genetic analysis.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full GTG profile View Profile

Genetic Technologies Timeline

March 06 2015

Related Articles

A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
December 03 2018
The readout of clinical trials is expected this month.
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use